Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings. Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES. Links: Register to view ADCES24 On-Demand Content: ADCES24 (adcesmeeting.org) Visit danatech: Diabetes technology for healthcare professionals | Danatech (adces.org) Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org) To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net) To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).: Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical Scenarios (0.75 CE/CME) Part 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies (1 CE/CME) Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER Program Visit diatribe: Making Sense of Diabetes | DiaTribe Visit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com) Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org) Find resources from DiabetesWise: Home » DiabetesWise
Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings.
Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES.
Links:
Register to view ADCES24 on-demand content: ADCES24 (adcesmeeting.org)
Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)
Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org)
To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net)
To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).:
Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER Program
Visit diatribe: Making Sense of Diabetes | DiaTribe
Visit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com)
Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org)
Find resources from DiabetesWise: Home » DiabetesWise
Kirsten Yehl
Hello, and welcome to ADCES's podcast, The Huddle: Conversations with the Diabetes Care Team”. In each episode, we speak with guests from across the diabetes care space to bring you perspectives, issues, and updates that elevate your role, inform your practice, and ignite your passion. I'm Kirsten Yehl, Director of Research and Development at the Association of Diabetes Care & Education Specialists.
It's always a pleasure to be able to talk with longtime ADCES member, Jane Seley, who this year was honored with the ADCES Allen Van Sonne Distinguished Service Award. I sat down with Jane live at the ADCES24 meeting to talk about all the latest in diabetes technology. Tune in to hear about some of the latest developments to look forward to this year. Please note that this episode was recorded at our booth in the exhibit hall, so you may hear some background noise throughout.
Jane, welcome to The Huddle.
Jane Seley
I'm so happy to be here, Kirsten. This is like the highlight of this meeting.
Kirsten
Well, I am so glad you let me pull you off of this floor. There's so much going on around here, and I know it can be engaging, I think. So I appreciate you letting me pull you in. And you're always my favorite person to talk to about technology. You know that. You're my go -to. So I would love to hear if you don't mind if I pick your brain?
Jane
Not at all. Let's go.
Kirsten
Let's go. OK. So around this conference on the floor, I'm just hearing about everything that's hot in technology, how technology is changing the landscape of diabetes care and education, and how the diabetes care and education specialist role is growing and changing. I know we're going to dive into some real specific details there, but I would just love to hear your thoughts on that big picture. Where is technology taking the specialty?
Jane
So here's some things that are interesting facts. By the end of 2022, it was over 800,000 people wearing insulin pumps. So you've got over 800,000 wearing pumps, and you have almost 3.2 million people by the end of 2022 using CGM. But what changed in 2022 with CGM is the mix of type one versus type two shifted and it went from more people with type one wearing the CGM to more people with type two wearing the CGM. But that's not so surprising in a way because there's so many less people with type one.
So it was just a matter of time that type two would take over. But I think it was probably tied to the change in reimbursement, because it used to be you had to take at least three shots a day of insulin and now you just need to take insulin. So it could be one shot of basal insulin and you're done. You could get reimbursed for it. So I think that this type two market for CGM is really going to grow because primary care is really becoming interested.
Kirsten
So the type two market is growing and maybe we can dive in a little more to that too, but can we do it alongside the over-the-counter CGMs? Because that could work for also the pre-diabetes market too, right? I mean, is there an interest there? I'd love to hear your perspective across the board there.
Jane
It's really interesting because we haven't had it before, we don't really know what it's gonna look like.
Kirsten
Yeah.
Jane
But there’s one product from Dexcom and two products from Libre that are gonna hit the market very soon, I think that probably the Dexcom Stelo will be out by the end of the summer. I'm not exactly sure. I haven't heard a date yet for the Lingo, which is a more wellness focused one, CGM for Abbott. And then there's the Rio that's for type two people that don't take insulin. They'll be coming. So over the counter means you can do whatever you want with it, really.
Kirsten
Yeah.
Jane
So indication isn't that important, but you're not seeking reimbursement also. So that means anyone on the whim that wants to see what happens when they eat a big bowl of pasta can do that.
Kirsten
Right.
Jane
So I think a lot of people are going to be very excited about this. I want to say that CGMs don't have to be worn all the time. And I think that people have to realize, especially we health care professionals, we have to realize that it's not an all or nothing proposition. And even with people who have reimbursement, they may have copays that add up for them, or people that have no insurance. They don't have to wear it every day.
I would be so super happy if they put one on at the first of every month and I had 10 to 14 days of data. That would give me a lot of information, more than checking their blood sugar with a meter once or twice a day, maybe four times if I'm lucky but unlikely. The other thing is people might want to wear it during certain times like when their medication's being adjusted or maybe they're going away to college and it's a whole new change of lifestyle and all and their parents want them to wear it. And then maybe later they don't want to, but maybe they wear it, this happens all the time, they wear it and it's like, wow, you know. So that's why I like professional CGMs because there's something that I can put on them. They don't have to learn how to do it. I'm placing it. All I ask is they peel it off like a bandaid, they give it back to me. I download it and I go over it with them and I show them all these like amazing discoveries, right?
So most people after they have that experience and we go over their data and I ask the questions, wow, look what happened here. What were you doing that night? What did you have for dinner? Did you walk after it? You know what I mean? So people say, hey, you know I want it all the time or at least some of the time.
Kirsten
And 80% of the population is still doing BGM, right?
Jane
Well globally, including the United States, 80% are still using BGM. It's fast, it's inexpensive, it's accessible all over the world. So we can't forget them and we need to be analyzing their data in the same way that we're analyzing people with CGM data. It's not fair not to.
Kirsten
Right.
Jane
And with CGM, we talk about time in range.
Kirsten
Right.
Jane
For most people, the time in range would be how much of the day and night are they spending in this 14-day period between 70 and 180. And we hope in order to have an A1C of less than 7%, that it's at least 70% of the time.
Kirsten
Right.
Jane
So that's great and we know how to look at these metrics and the AGP or Ambulatory Glucose Profile Report guides you through the metrics that you look at. They should be below 54 glucose levels, less than 1% of the time. They should be below 70, less than 4% of the time. The time in range, 70% of the time and the remainder would be hyperglycemia. So we know those numbers, but it's a little bit more difficult with the glucose meters because you have big holes of no data. So, some of the meter companies are working on ways and hoping to come out with an HEP report that really is geared for people using meters. Okay, that's coming. They're going to call it probably readings in range.
Kirsten
Really?
Jane
Yes.
Kirsten
Okay, I love it.
Jane
So we're going to analyze all of those different levels to see how many readings are in those ranges and we're going to come up with metrics. So this is a work in progress.
Kirsten
So I do want to jump into pumps and start talking about the advances in pumps. There's some incredible stuff I'm seeing on the floor. But I think before we do that, let's finish up CGM. Anything else on CGMs you want to talk about?
Jane
So I was just very excited to hear here on the exhibit floor, EverSense has already submitted to the FDA for an advancement in their product that the wear time will be 365 days.
Kirsten
You're kidding me.
Jane
So they're going to go from 180 to 365, and the submission is in the US, it's not in Europe. We would get it first. So, think about the proposition of inserting this device into someone and having to do it originally, it was only 90 days, and you have to take it out, put a new one in, the person doing it has to be properly trained in how to do that, and here's a small procedure that is done in the office. And it was not the greatest adoption when it was every 90 days.
I thought when it went to 180 days, it would grow exponentially. And it's very accurate, it's really a good device, but it didn't quite do that. So they're also gonna go, the fact that you could wear it twice as long, but once a year you put it in and you're done, it has other features that are, so the calibration would only be once a week, instead of once a day. So that's a big difference right there.
Kirsten
That's gonna be a game changer when it comes out.
Jane
I think it is, I do think it is. Athletes like it because it's inside, you can't knock it off. I hate to say this, but a friend of mine that came here, on her way to come here, she wears an AID pump and she bumped her sensor against the wall in her apartment as she was going out with her suitcase. And it seemed to be fine, but by the time she got on the plane, it failed.
Kirsten
Oh, no.
Jane
You know, these things happen and what if you're out all day and she's on the plane, stuff's in her suitcase, you know, in this, those are terrible inconveniences. Having it under your skin, safe and intact, is something to be said.
Kirsten
Something to be said for it, and especially if you only go in once a year to have it in place.
Jane
And they're working with insulin delivery devices, pumps, and I would imagine smart pens and things like that, that will have integration. The other thing about EverSense is they have a team of trained people that can do it. So no longer does your practice have to figure out who's going to be doing it or sending them to a competitor hospital down the street. You know, which you're not likely to want to do. They actually have trainers that are very equipped to doing this and do it on a regular basis. Most of them are nurse practitioners or PAs who can meet up with the patient and put it in. So this makes everything different.
Kirsten
So is this a new development or is this…?
Jane
Having the trainers that can do it, and could arrange with them. I guess they have places to do it. I think it's going to make a difference. A lot of people don't know that though, so spreading the word.
Kirsten
Yeah, no, that's kind of a big deal, especially for the provider community. Okay, let's talk about pumps. We'll talk about pumps and then talk about pens right after that. Okay, Jane, I'm gonna like give you the floor. Let's talk through Medtronic, Tandem, Omnipod, Twist. Let's go for it.
Jane
Okay, let me start with Medtronic. I'm just gonna highlight what's new that is making people really happy about it.
Kirsten
Yeah.
Jane
The new sensor right now, the Guardian 4, seems to be quite good. So automated insulin delivery is kind of like a marriage, right? You've got to have a good pump. You have to have a good sensor and you have to have a good algorithm. It's those three things together. So if you don't have a good sensor, all bets are off. So I think that Medtronic has got their game back now because they have a good sensor. They have a seven-day infusion that a lot of people are truly wearing for six or seven days. So that's nice. And they have, their algorithm is more sensitive to when people are eating. So it's looking at a sudden, you know, increase and the duration of the increase to give you some help with mealtime dosing. We're going to see more and more of that in the future. All of the pumps are working on that. Medtronic is one of the first ones to get involved. So I think that's really cool. Tandem must be on top of the world that they not only have the T-Slim, but they also have the Mobi, using the same control IQ algorithm. And I think that's a good thing, because people are very comfortable with that algorithm and have had really good results with that algorithm. Sometimes when a new product comes out, people are like, “wait a minute, let me watch and see”. They know the other algorithm. I have people on the old basal IQ algorithm, which they're no longer encouraging people to use. They're not really supporting anymore. They won't get off it.
People are like that. If it's not broken, they want it. So having the control IQ algorithm in the Mobi, I think is a good thing. Now it has a five-inch tubing, so it's like a convertible patch to tether, right? And it has this cute little thing that goes over it, which you can actually wash and reuse. The number of times varies. Imagine it has to do with your detergent use and how you wash it. But that saves money that you don't have to keep getting new ones as often and you can wear it quite comfortably. It's very light. Oh my God, I can't believe how light it is. It's nothing, even filled. So I have had people really excited about it. It's also very intuitive.
A friend came to visit me recently wearing it and she had just put it on and was super excited about it, and she's a nurse practitioner herself. And my thing is I want to use it. So, the whole day that she spent with me and some other friends, I was bolusing her. I didn't have to ask her a single question. I could figure out everything that I wanted to do. And she made it through the day, so it must have worked. And the other thing is the OP-5, many people are very happy with the algorithm. But I think what we're most happy about is we didn't really have a true patch pump that had automated insulin delivery. And a lot of people were waiting for that and weren't going to pump therapy.
Kirsten
So Jane, what about Beta Bionics? That's a big one too, right?
Jane
It sure is. And Beta Bionics is going places. First of all, right now the pump that's available is just insulin delivery. But they're working on, and the studies are beginning soon, on having a dual hormone pump with glucagon. That could wind up being a groundbreaking thing. I know this has been tried in the past, but we never had such stable liquid glucagon like we have now from those former studies. What I like about Beta Bionics is it's a really simple plan for an automated insulin delivery device. And what's simple is that even primary care could start someone on it, because pretty much all they do is have to put the person's weight in and you go. It also makes meal capture very easy because it's based on meal size. And the meal size is either their usual amount of food that they eat or less or more. That's all the decision they have to make of their usual. But it makes it so that they don't have to learn how to carb count. That's what's important about this is they don't have to carb count. It's very simple. I think for people that trust the pump and want to let it just do its thing, they're going to do way better than with injection. So that's what I like about it.
So I'm looking forward to that dual hormone to see the data on that. I don't know when it's going to be a while, but, and for people to have access to the islet Beta Bionics pump because I think it's a very interesting product. Or they might switch to it. If they're already using an AID and they're going to the Bahamas for a week, they could switch to it and have the ability to go in the water and everything and not worry about it. And a lot of people do. Or the whole summer, or the kid goes to camp for the summer, things like that. There's circumstances when people wear it intermittently. I don't care. If that makes people happy. It's great to have the flexibility. We're going in the direction of no one size fits all anymore with pump systems. There's going to be more freedom of choice of which sensor you want to use for that pump.
Kirsten
So that's where the diabetes care and education specialist comes in, right? Like this is the key, that the specialty can help you choose the right system for you.
Jane
So our role has really been elevated with the great integration of pumps and sensors into care, because our colleagues in many disciplines don't have the time and don't have the patient relationships that we already have to get people to use these devices with the most benefit. So I feel like we really have the leg up in this. You know, that we can teach people, you know, “what are you eating, when are you eating, when do you exercise?” We put everything together for them. We just don't tell them how to press buttons and put things on and how to clean your skin. We get into the, you know, the devil's in the details. So that people are comfortable wearing the device. It's staying on. They're not knocking it off. They're getting the results they're looking for. And if they're not, we play detective. That's what we're best at. So I think that the diabetes care and education specialist is one of the most important people in an endocrine team to get people to get to their goals.
Kirsten
So when I use that endocrine team, what about primary care? Maybe we should jump over there.
Jane
Well, primary care has to start taking ownership of CGM and smart pens and caps. So primary care, how do you make that happen? You have to make them comfortable with onboarding the device, having the person understand how to put it on, take it off, and having them understand the report. So you should have them learn how to read an AGP report. They don't have to know all the details. For example, I'm integrating Libre soon into Epic at New York Presbyterian Cornell, where I work, and we're gonna have three different drop-downs of reports that you could choose. So you could either choose first drop-down is just the AGP report, the second drop-down was still kind of tinkering, but it's probably gonna be AGP report, day-by-day and weekly summary, and then the third one is everything. And now I've decided to add a fourth one for pregnancy.
Kirsten
Fantastic.
Jane
Because some of the reports will accommodate the change targets for pregnancy so you can get what you need if someone's pregnant. So the easier I make it for people to get the data, because once you're signed up with the device, the data's right there in Epic.
Kirsten
Exactly, exactly.
Jane
This is what we need, you know?
Kirsten
Well, can I ask you, okay, let's just say it's like in this perfect world, if primary care understood the AGP report, understood really what time and range is, and understood how to work with patients. And then let's add in GRI, right? Glycemic Risk Index. What do you think about that being? If you could measure a glycemic risk index and say, here's the risk, this is when somebody really needs to go see a specialist, right? Like we can handle you, we can handle some in primary care, but do you think that the GRI could ever indicate, you know what, there's something happening here that's putting you at risk, you need to see an endocrinologist. I think that's where the balance could come in. That would allow primary care to say, you can handle this, but it's when it gets to this point that a specialist needs to come in.
Jane
So let me explain.
Kirsten
OK.
Jane
I'm so glad you wrote this up. So the Glycemic Risk Index was created by a group of really smart people globally for the Diabetes Technology Society. So this was an idea of David Klonoff's. And what they did was they sent out tracings of people's sensors. And you had to evaluate the tracings and say what you thought it meant, right? So people got a series of tracings and they scored them. And then the statistician looked at the scores to see how people jived, where things were high and low and how often. And then he did an amazing job at coming out with a mathematical calculation of all of the metrics in the AGP report.
So instead of just saying that someone's time and range, which should be between 70 and 180, is 72%, he could have a million highs and a million lows.
Kirsten
Exactly, that's putting him at risk.
Jane
He came up with a composite score. So he weighed different aspects of the metrics of the very high, the high, the in range, the low, and the very low. And he gave them different rankings based on the severity of how people calculated the risk for people reading these tracings. And then we had a number of meetings with a lot of people to come to consensus on what this all meant and what a report should look like. And then I, of course, opened my big mouth and said, wait a minute, this is going to give a single number that's based on all these factors. How amazing would it be if we could figure out what number would be the tipping point to send the person to endocrine?
Kirsten
Exactly.
Jane
So you agree?
Kirsten
I totally agree.
Jane
It was my crazy idea.
Kirsten
I love your crazy ideas, Jane.
Jane
And I think it's a good one because they can know for different kinds of populations, like older adults, it might be a different number. People that are pregnant, of course, would be a different number and so on, when endocrine is the best plan because there's so many people with diabetes in this country. The number keeps growing and you know, primary care has to step up and do more of it.
Kirsten
So I think the support goes back to, this could empower primary care to take on CGM reading and supporting people with diabetes, along with diabetes care and education specialists in working hand in hand with primary care.
Kirsten
Okay, well here all over the floor, a big hoopla, is the Sequel Twist. Can you talk about it? And I did see a great picture with you and Dean Coleman. Is it Coleman?
Jane
Cayman.
Kirsten
Cayman. You got that right. Oh my gosh. Yeah.
Jane
So the inventor of the Twist is the same person that invented the first insulin pump that came to market.
Kirsten
Right.
Jane
And he's a very smart guy. It looks like it's going to be really interesting. It's a round circle. It holds 300 units of insulin. It has a mechanism in it inside that as the insulin comes out, it goes around in a circle and it measures it four times to make sure the accuracy is correct. So it looks like it's really accurate. The best part about it, I think, is that it's using the tidepool looping algorithm that's approved by FDA. So this is the first home for the tidepool algorithm for looping. So this is going to open up legitimate ties actually, looping. Because one of our problems with people that are looping is we can support them, but it's not FDA approved.
Kirsten
Exactly.
Jane
Some people have a real problem with that. I don't blame them, but I feel it. I can look at the numbers and be another pair of eyes for the person, not leave them alone with it, because they're doing that thing they're not supposed to do. They are supposed to do whatever they need to do to manage their diabetes. So I don't think there's any barriers there. But this met FDA approval, so it's got to be a good algorithm. It's a very big deal.
Kirsten
Now, would you say this is one of the biggest things we're going to see over the next year? What do you think is the biggest news? OK, Twist is big news. What else is big news on this floor?
Jane
Well, it's not out yet. But once weekly basal insulin is going to be huge.
Kirsten
Wow, that is right. Okay.
Jane
So let's say you had type two diabetes and you needed mealtime insulin and you didn't want to do all that work. You really hated taking injections. What about if you only had to take once a week basal insulin and then you could wear a very simple pump that's designed for type two, that's a patch pump that you can put on for three days, let's say. Like the secure simplicity. And every time you either need to correct, you press buttons. Now, I think that product is really cool, but it has its limitations because every pressing button is two units. But I'm sure they know that and I'm sure they're working on being able to have one, maybe one-unit buttons. How could they not? And that would make it open to people with type one also that don't want to take a lot of shots when they're out and about but aren't ready for a full-service pump. It might be good as people age and they can't take a more sophisticated device. This might be a good transition device.
Kirsten
Yeah.
Jane
So I think things like that. V-Go is another one. It's changed every day. It has both the basal and the bolus. It has its limitations though. So I think in the future, all of these devices for type two insulin delivery that are simple and easy to use, we have the Inpen getting smarter and smarter and smarter.
Kirsten
Yep.
Jane
So that's getting great.
Kirsten
How about Bigfoot?
Jane
Well, Bigfoot took a pause, Abbott bought it, and before they bring it back out, I know they must be doing amazing things to it.
Kirsten
Okay.
Jane
So I'm hoping, this is just my hope, we'll see what happens. But Bigfoot captured that you took a dose on this day at this time, but it didn't capture the dose. Inpen captures the dose. I want to know the dose.
Kirsten
Yeah.
Jane
So I'm guessing that's what they're working on.
Kirsten
So you think that's going to be over the next year and that's probably something to look out for in pens…?
Jane
Yeah. Also, insulin companies are working with smart pen systems. Like Lilly has the Tempo, which works with an app.
Kirsten
Resources. Like can you talk through a few resources that, like there's just so much here. It is overwhelming when you walk on this floor. I mean, you've wrapped it up for us really well, but like if you're not here, where do you go to figure all of it out?
Jane
So I want to bring up a couple of great resources for my peers if they're not aware of them or they've kind of forgotten about it maybe over time, I do that sometimes, that I really like. So first one up of course is ADCES danatech. Danatech keeps growing and growing and growing and growing. So there's all kinds of videos and modules to learn all the kinds of things you want to learn about using technology. There's position papers and guidelines. Lots of really good pieces of information. There's also, I don't know if you remember, but if you, I know you remember, Kirsten, but for the listener. I don’t know if you remember, but several years ago, ADCES sponsored a paper on competencies for diabetes. And it's the competencies by your role and your licensure, but also by your setting.
Kirsten
And these are the technology competencies, right?
Jane
Right.
Kirsten
That's what we worked on together.
Jane
Right. So this is specific to technology.
Kirsten
Yep.
Jane
And it's a great paper and it has some nice graphics to look at. You could look at it if you work in a camp and you're an RN, what level you should be at. But they took it a step further. I'd like to take credit for it, but I had nothing to do with it. It's all about you, Kirsten. They made a tool so you can actually go to this tool and drop down and enter like what your role is, what your setting is and so on. And boom, it tells you your competencies. I love that. The next one up is The American Diabetes Association has a tool called the Consumer Guide. The Consumer Guide is all things diabetes. It's not just devices. It's also all kinds of products like infusion sets and hypoglycemia treatment. Like the two newest ones I love, Gvoke and Baqsimi, which are really simple to use and easy to learn. So it's easy for the non -diabetes person to know how to use it. All of that's there and you can compare products. It has a compare feature. We can compare up to three products together. All the meds were there, everything is there.
And the next one I want to mention is Diabetes Wise. It's out of Stanford. It's funded by Helmsley Trusts. And it's really awesome. They update things really, really fast. So there's two versions of Diabetes Wise. There's a patient one and a professional one. The patient one right now is available in English and Spanish. They're talking about adding more languages. So at least we Spanish speakers have it. The professionals called Diabetes Wise Pro is for health care professionals. So you could be in a session with somebody if you're interested in insulin pump. The next one, the PANTHER program, which is out of University of Denver, they have handouts on all of these devices, which are teaching tools and also for us. They put them out very quickly. So for example, when Twist hits the market, they'll already have the tool.
Kirsten
That's fantastic.
Jane
They have it for Beta Bionics. I mean, within weeks of it coming to market, they had a tool on it. Because I went to look because I didn't have anything, you know, and there it was. And they're really well written, low reading level, really terrific. The DiaTribe magazine for people living with diabetes is very technology heavy in the kinds of articles they write. They're really from the heart, you know, articles that give you the pros and the cons and they really have done their homework and they discuss the devices. So I think it's very important. I tell patients all about it. Give them the website. And the last thing I want to mention is the E, M like Mary, P like Paul, R like Roger. EMPR, which stands for Medical Professionals Reference. You can go on their website, free open access. You can go to charts, and then you can go to endocrine, and then you can go to diabetes. So it's not so hard to figure that out. And once you go to diabetes, there's these great charts, easy to read, on all the medications. There's one on diabetes treatments, that's everything but insulin. There's one on insulin, there's one on insulin pens, there's glucose meters, there's CGMs, all separate charts that give you all the products where you can compare. Those are my favorite things.
Kirsten
These are my favorite things too.
Jane
Really?
Kirsten
Of course, of course Danatech is at the top, I have to, well it's at the top. We appreciate that. So Jane, I hate to do this, but we are totally at the end of our time. I just, if you can leave us with one thing. I mean, I love our conversations. I totally appreciate you letting me pull you off the floor. It's been an amazing talk. What is like one big thing, like what is the biggest thing in tech that you found on this floor that you want to leave our listeners with?
Jane
Oh my God, it’s such a hard question. I guess what I would want to say is there's a lot of choices. And the most important thing is that this has to be the person with diabetes’ choice, with us guiding them, giving them information, helping them figure out what's for them and what's not, and offering it to everyone. For example, CGM, I should make no assumptions. I should make an effort, especially now we have the over-the-counter and other ways. We have samples in the office we give people. Everybody should have access to CGMs in this day and age. At least some of the time. We put professionals on and actually building it on and downloading it and interpreting it. So I want to make sure that everybody gets what's appropriate for them given their clinical circumstances, what they need and what they can support.
Kirsten
Right. That is, I have no other words to say, but that's very beautiful. And you are honestly reflecting everything that's been on my mind too, as we talk through all of this. This technology should be for everybody.
Jane
One size does not fit all.
Kirsten
Absolutely. Absolutely.
Jane
Thank you so much. This was a great conversation.
Kirsten
Thank you, Jane. Always a great conversation. And we're going to get to have you on again, right?
Jane
Of course.
Kirsten
Thank you for listening to this episode of The Huddle. Make sure to download the resources discussed on today's episode. You can find them linked in the show notes. And remember, being an ADCES member gets you access to many resources, education, and networking opportunities. Learn about the many benefits of ADCES membership at adces.org/join. The information in this podcast is for informational purposes only. It may not be appropriate or applicable for your individual circumstances. This podcast does not provide medical or professional advice and is not a substitute for consultation with a health care professional. Please consult your health care professional for any medical questions.